Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

Area soci

Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da GdS SIBioC - Medicina di Laboratorio Marcatori Cardiaci

Rilevanza clinica e interpretazione dei marcatori biochimici nello scompenso cardiaco
Clinical relevance and interpretation of biochemical markers in heart failure
F. Franzini \| S. Masotti \| C. Prontera \| A. Clerico \| GdS SIBioC - Medicina di Laboratorio Marcatori Cardiaci \|
<p>Heart failure (HF) is a global problem with an estimated prevalence of 38 million patients worldwide. Both prevalence and incidence of HF increase progressively with population ageing (prevalence ≥10% in people >75 years), especially in the high-income countries. HF is considered as the fatal event of all cardiovascular disorders. Despite some progress in diagnosis and treatment, its prognosis is worse than that of most cancers. The disease is heterogeneous in its clinical presentation and the diagnosis is not based on a single test, but on a combination of the history, physical examination and appropriate investigations, including some laboratory tests. As a consequence, the accuracy of diagnosis by clinical signs alone is often inadequate, especially in the early asymptomatic stage of HF. For these reasons, there is an increasing interest in the development of new biomarkers useful for the diagnosis, prognosis and follow-up of patients with HF. The aim of this paper is to provide an overview of biomarkers recommended by international guidelines for HF, discussing their clinical impact and the interpretation of results. Furthermore, a possible strategy for the development and evaluation of novel prognostic biomarkers for HF will be suggested.</p>
Biochimica Clinica ; 39(4) 241-255 Rassegne - Reviews